Advertisement
UK markets open in 3 hours 23 minutes

  • NIKKEI 225

    37,818.11
    -641.97 (-1.67%)
     

  • HANG SENG

    17,340.70
    +139.43 (+0.81%)
     

  • CRUDE OIL

    82.77
    -0.04 (-0.05%)
     

  • GOLD FUTURES

    2,321.40
    -17.00 (-0.73%)
     

  • DOW

    38,460.92
    -42.77 (-0.11%)
     

  • Bitcoin GBP

    51,646.89
    -1,819.02 (-3.40%)
     

  • CMC Crypto 200

    1,389.55
    -34.55 (-2.43%)
     

  • NASDAQ Composite

    15,712.75
    +16.11 (+0.10%)
     

  • UK FTSE All Share

    4,374.06
    -4.69 (-0.11%)
     
Money:

The five essential pieces of financial paperwork you must never lose

Mislaying key documents can cause real headaches, so it’s worth tracking down these most commonly-lost bits of paperwork

Global Pneumonia Therapeutics Market (2021 to 2030) - by Therapeutics, Distribution Channel, Age Group and Region

Research and Markets
·6-min read

Dublin, Nov. 05, 2021 (GLOBE NEWSWIRE) -- The "Pneumonia Therapeutics Market by Therapeutics, Distribution Channel, and Age Group: Global Opportunity Analysis and Industry Forecast, 2021-2030" report has been added to ResearchAndMarkets.com's offering.

The global pneumonia therapeutics market was valued at $12,293.9 million in 2020, and is projected to reach $25,546.8 million by 2030, registering a CAGR of 8.5% from 2021 to 2030.

Pneumonia is an infection that affects the lower respiratory tract. Furthermore, pneumonia is characterized by symptoms such as short breathing, fever, chest pain, nausea, and vomiting. In pneumonia, the air sacs of lungs called as alveoli are filled with fluid or pus that cause inflammation. It is majorly caused by microorganisms such as fungi, bacteria, virus, and parasites, and mostly affects people with weakened immune systems, and is common in children and older people.

The growth of the global pneumonia therapeutics market is majorly driven by rise in incidence of pneumonia. In addition, increase in prevalence community-acquired pneumonia is expected to propel the industry growth during the forecast period. Furthermore, increase in product launches after FDA approval is expected to help the industry gain maximum revenue. In addition, surge in clinical trials for the R&D of for development of vaccines and drug molecules is projected to help the industry grow in the next few years. However, implementation of stringent regulations for vaccines and drugs hinders the market growth.

The global pneumonia therapeutics market is segmented into therapeutics, distribution channel, age group, and region. On the basis of therapeutics, the market is categorized into prevention vaccines, and treatment drugs. By distribution channel, it is classified into hospitals, pharmaceutical stores, and others. Depending on age group, it is segregated into pediatric, adult, and geriatric. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Benefits

  • The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.

  • It offers a quantitative analysis from 2020 to 2030, which is expected to enable the stakeholders to capitalize on the prevailing market opportunities.

  • A comprehensive analysis of factors that drive and restrain the growth of the market is provided.

  • The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the market.

Key Topics Covered:

CHAPTER 1: INTRODUCTION

CHAPTER 2: EXECUTIVE SUMMARY

CHAPTER 3: MARKET LANDSCAPE
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. Porter's five force analysis
3.4. Top player positioning, 2020
3.5. Market dynamics
3.5.1. Drivers
3.5.1.1. Increase in prevalence of pneumonia
3.5.1.2. Upsurge in geriatric population with weaker immune systems
3.5.1.3. Increase in incidence and spending for community-acquired pneumonia
3.5.1.4. Surge in number of product launches
3.5.2. Restraint
3.5.2.1. High price of pneumonia therapeutics
3.5.3. Opportunity
3.5.3.1. Outbreak of novel viruses attacking respiratory system
3.5.4. Impact analysis
3.6. COVID-19 Impact analysis on the pneumonia therapeutics market

CHAPTER 4: PNEUMONIA THERAPEUTICS MARKET, BY THERAPEUTICS
4.1. Overview
4.1.1. Market size and forecast
4.2. Prevention vaccines
4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast
4.2.3. Market analysis, by country
4.2.4. Market analysis, by distribution channel
4.3. Treatment drugs
4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast
4.3.3. Market analysis, by country
4.3.4. Market analysis, by distribution channel

CHAPTER 5: PNEUMONIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL
5.1. Overview
5.1.1. Market size and forecast
5.2. Hospitals
5.2.1. Market size and forecast
5.2.2. Market analysis, by country
5.3. Pharmaceutical stores
5.3.1. Market size and forecast
5.3.2. Market analysis, by country
5.4. Others
5.4.1. Market size and forecast
5.4.2. Market analysis, by country

CHAPTER 6: PNEUMONIA THERAPEUTICS MARKET, BY AGE GROUP
6.1. Overview
6.1.1. Market size and forecast
6.2. Pediatric
6.2.1. Market size and forecast, by region
6.2.2. Market analysis, by country
6.3. Adult
6.3.1. Market size and forecast, by region
6.3.2. Market analysis, by country
6.4. Geriatric
6.4.1. Market size and forecast, by region
6.4.2. Market analysis, by country

CHAPTER 7: PNEUMONIA THERAPEUTICS MARKET, BY REGION

CHAPTER 8: COMPANY PROFILES
8.1. ABBOTT LABORATORIES
8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product portfolio
8.1.5. Business performance
8.1.6. Key strategic moves and developments
8.2. BAYER AG
8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product portfolio
8.2.5. Business performance
8.3. ELI LILLY & COMPANY
8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Product portfolio
8.3.5. Business performance
8.4. GlaxoSmithKline PLC
8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Product portfolio
8.4.5. Business performance
8.5. LUPIN PHARMACEUTICALS, INC.
8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Product portfolio
8.5.5. Business performance
8.5.6. Key strategic moves and developments
8.6. MERCK KGAA
8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Product portfolio
8.6.5. Business performance
8.6.6. Key strategic moves and developments
8.7. NOVARTIS AG
8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Product portfolio
8.7.5. Business performance
8.7.6. Key strategic moves and developments
8.8. PFIZER, INC.
8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Product portfolio
8.8.5. Business performance
8.8.6. Key strategic moves and developments
8.9. SANOFI S. A.
8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Product portfolio
8.9.5. Business performance
8.10. TEVA PHARMACEUTICALS INDUSTRIES LIMITED
8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Product portfolio
8.10.5. Business performance

For more information about this report visit https://www.researchandmarkets.com/r/12yhok

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900